Compass Pathways PLC focuses on developing therapies for mental health conditions, particularly treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). The company is advancing its lead product, COMP360, a psilocybin-based treatment, through clinical trials to demonstrate its efficacy and safety. Compass Pathways operates primarily in the biopharmaceutical sector, targeting healthcare providers and patients in need of new treatment options for mental health disorders.
